+3%

est. 2Y upside i

HealthcareSeries A

Rank

#1990

Sector

Digital Health

Est. Liquidity

~3Y

Data Quality

Data: Low

Agebold offers a strong moat and recent CMS win, but the $90M valuation implies a 8.4x multiple on estimated $10.7M ARR, above public comps.

Last updated: July 3, 2026

Bull (20%)+101%

Revenue grows to $19.8M by 2028 with 8x exit multiple from an IPO window, yielding $158.4M exit. Common stock after preference and 20% dilution appreciates ~101%.

Base (45%)+26%

Revenue reaches $19.8M with 5x multiple in line with public comps, exiting at $99M. Common stock gains ~26% net of preference and dilution.

Bear (35%)-84%

Revenue stalls and multiple compresses to 2x, exit at $39.6M. Preferred takes $27M, common recovers $12.6M, and 20% dilution leads to ~84% loss.

Est. time to liquidity~3.0 years

Preference Stack Risk

high

Funding Intensity

30%

Total funding $27M represents 30% of $90M valuation, creating ~$27M preference overhang.

Dilution Risk

high

Runway from Sep 2023 $17M round likely exhausted; further raise within 2 years expected to dilute common by ~20%.

Secondary Liquidity

none

No secondary market transactions have been reported, indicating limited liquidity for employee shares.

Other — 9 roles

View all 9 open roles at Agebold →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Agebold's data — designed to show you've done your homework.

  • 1

    “How does the company plan to scale B2B2C sales beyond existing Medicare Advantage plan partners?”

  • 2

    “What is the current cash burn rate and how does the leadership view the need for additional funding?”

  • 3

    “Can you walk through the employee equity structure, including any anti-dilution provisions or liquidity rights?”

Community

Valuation Sentiment

Our model estimates +3% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.